Agilent currently sells software for the chemical, environmental and pharmaceutical manufacturing markets in India. Its goal is to capitalize on that country’s microarray market, which is expected to increase by 70% percent this year, by expanding its presence in industries such as medical research, drug discovery and agro-biotech.
Growth in sectors like biopharmaceuticals, contract research bioservices, agriculture, genetic engineering and molecular medicine will drive growth for analytical instrumentation, stated Sanjeev Dhar, country manager for the Life Sciences and Chemical Analysis (LSCA) business in India.
Agilent said its DNA microarray-based genomics technology aims to improve the productivity of gene-expression and genomics research. Microarrays, also known as DNA chips or biochips, are small pieces of glass dotted with strands of DNA, each of which corresponds to a specific gene in the genome. In a single experiment, microarrays are said to be able to measure genome-wide differences between diseased and healthy cells.
